The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1350
Rifaximin (Xifaxan 550) for Hepatic Encephalopathy
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.

The FDA has approved a new 550-mg tablet of rifaximin (Xifaxan – Salix), a minimally absorbed oral antibiotic, to reduce the risk of recurrent hepatic encephalopathy (HE). A 200-mg tablet has been available for treatment of travelers’ diarrhea since 2004.

TREATMENT OF HE — Excess ammonia in the systemic circulation is thought to be a factor in the development of HE. One source of ammonia is urea breakdown by bacteria in the intestinal lumen.1 Antibiotics such as neomycin or metronidazole (Flagyl, and others) reduce ammonia production by eradicating urease-producing bacteria in the gut, but their use has been limited by toxicity, drug-drug interactions, and concerns about selection of resistant bacteria.2 Non-absorbable disaccharides, such as lactulose, are thought to decrease the absorption of ammonia from the gut by lowering the pH of the lumen and by ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: Rifaximin (Xifaxan 550) for Hepatic Encephalopathy
Article code: 1350c
 Electronic, downloadable article - $45
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian